HPV Vaccine Rates in Alberta: Impact of the Pandemic and Program Changes
We studied HPV vaccination data across alberta to understand how rates changed before and after the COVID-19 pandemic, focusing on people vaccinated outside of school programs. Our research suggests that making the vaccine available to more people based on age, rather than risk factors, may have helped lessen the negative effects of disruptions caused by the pandemic.
Vaccination rates for those aged 18-21 and 22-26, who were directly affected by the new age-based program, didn’t drop much during the first part of the pandemic (2020, 2021). Actually, rates were similar or even higher in the following years (2022, 2023). however, the 16-17 age group, who didn’t have changes to vaccine funding, experienced the biggest and longest declines in vaccination rates.
A study in the US showed larger drops in adult vaccinations during the pandemic (not just HPV), with rates falling by as much as 70% and staying low in 2022 [22]. We saw smaller changes, likely as of the shift to an age-based program. We also noticed a significant increase in vaccinations given at college and university health centers after the pandemic was declared and the age-based program started. This suggests a greater focus on vaccinating people 18 and older.
Throughout our study, we found that fewer males were vaccinated compared to females.This was surprising because, during the earlier risk-based program, males had better access to free vaccines. also,more unvaccinated people were male during our study period,as they weren’t included in school-based programs until 2014,six years after the program started for females.
Though, this finding aligns with generally lower vaccination rates among males. As of 2023,about 46.9% of Canadian males aged 18-26 were vaccinated against HPV, compared to 77.3% of females [23].Several factors contribute to this difference. Healthcare providers may encourage vaccination more often for females, possibly because they know less about the importance of male vaccination [24] or because they can combine vaccination discussions with routine cancer screenings for women [25].The previous risk-based program required people to share their sexual orientation to get a free vaccine, which likely discouraged some from getting vaccinated. A Canadian study found that only 26-56% of men eligible for free vaccination reported disclosing their sexual behavior to their doctor [13].It’s vital to find out if the males getting vaccinated now, under the age-based program, have similar risk factors as those vaccinated during the risk-based program.
We also found that people who moved to Alberta after age 16, when school-based programs were already in place, made up a large portion of those vaccinated during the risk-based program. This number increased during the age-based program.
References:
- [22] Source for US vaccination rate decline.
- [23] Source for Canadian HPV vaccination coverage rates.
- [13] Source for Canadian study on disclosure of sexual behavior.
- [24] Source for provider knowledge of male HPV vaccination.
- [25] Source for synergy with female cancer screening.
Worth a look
- Ask Your Medical Science Questions to NPR
- 2026 Chuseok Subsidy: How to Claim Up to 500,000 KRW in Your Local Area
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)